Furthermore, a study found that monocyte chemoattractant protein-1 (MCP-1) is elevated specifically in ADEs during the subjective cognitive decline (SCD) stage of AD, despite unchanged plasma levels [70]. This evidence concerns the gene CCL2 and Alzheimer disease.